OBJECTIVES The purpose of this study was to determine whether chronic obstructive pulmonary disease (COPD) is associated with sudden cardiac death (SCD) in the community.
and the rate of decline (7) of the forced expiratory volume in the first second has been linked to risk of coronary artery disease (CAD).
Of all manifestations of cardiovascular disease, sudden cardiac death (SCD) is the most lethal, with <10% survival on average (8) . Whether COPD is linked to SCD is important both from a mechanistic risk perspective and from the point of view of primary prevention of SCD, since COPD is often encountered as a comorbidity. Although some studies have suggested that COPD may be a risk factor for SCD (9) , robust population-based data are scarce. It is also important to consider this question in the context of associated medications such as short-acting beta-2 agonists (SBAs) that may be independently proarrhythmic (10) . Furthermore, because COPD prevalence increases with age, cardiovascular risk factors and CAD often coexist, and these need to be accounted for as well. One of the difficulties in studying SCD in the community is that pre-arrest clinical details are often sparse, and information is mostly limited to that gathered by emergency medical services (EMS). Through the Oregon Sudden Unexpected Death Study (Oregon-SUDS), a prospective, population-based study of SCD in the Portland, Oregon, metropolitan area, we have established a mechanism to systematically obtain lifetime clinical history for all SCD victims. We therefore performed a comprehensive evaluation of the association between COPD and SCD in the community.
METHODS
STUDY POPULATION. The Oregon-SUDS is an ongoing, community-based study of SCD using prospective multiple-source case ascertainment. Detailed methods have been published previously (11, 12) . Narayanan et al. We further performed sensitivity analysis using propensity score matching. The propensity matching was performed with PROC LOGISTIC (SAS version 9.3 SAS Institute, Cary, North Carolina) and a macro for 1-to-1 case-control propensity score matching, according to methods described by Parsons (14) .
First, we calculated each subject's propensity score in a logistic regression model with COPD as the outcome variable, using the following covariates: age, sex, smoking status, diabetes mellitus, hypertension, LVEF, and medications, including angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and SBAs. On the basis of the predicted probability of COPD (propensity score) from the logistic regression model, case subjects were then matched to control subjects with the closest propensity score by use of nearest-neighbor matching using a 2-digit match to achieve matching while preserving sample size (i.e., subjects were matched if both the case and control subject had propensity scores that were identical in the first significant digit [the tenths], with the hundredths allowed to range from 0.01 to 0.09 for a matched pair), which resulted in a dataset with 330 case and control subjects each.
We also performed additional sensitivity analysis with stronger matching (3-digit matching, with propensity score tenths and hundredths required to be identical); the resultant dataset had 418 patients (209 case and control subjects respectively). The association of COPD with SCD in the propensity score- 
RESULTS
SUBJECT CHARACTERISTICS. Initial analysis was performed in 728 SCD case subjects and 548 control subjects with CAD. Clinical and demographic characteristics of case and control subjects are outlined in Implantable cardioverter-defibrillators (ICDs) were present only in a minority of SCD case subjects (3.6%) and control subjects (0.5%).
COPD AND MEDICATIONS. COPD was significantly more prevalent in case subjects than in control subjects (30.8% vs. 12.8%; p < 0.0001) (Figure 1 ). The prevalence of asthma was not significantly different (9.8% vs. 9.1%; p ¼ 0. 71). Case subjects were significantly more likely to be taking SBAs (22.3% vs. 12.6%; p < 0.0001) ( Figure 1 ) and were less likely to be taking beta-blockers (60.6% vs. 66.4%; p ¼ 0.03). Only a small percentage of case and control subjects were taking long-acting beta-2 agonists, which was Values are mean AE SD or n (%). BMI information available for 632 case subjects and 528 control subjects.
Smoking status available for 565 case subjects and 396 control subjects. Cholesterol information available for 417 case subjects and 437 control subjects. Heart rate measurement available for 523 case subjects and 529 control subjects. QTc measurement available for 458 case subjects and 518 control subjects.
ACEI ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin receptor blockers; BMI ¼ body mass index; COPD ¼ chronic obstructive pulmonary disease; LVEF ¼ left ventricular ejection fraction; QTc ¼ corrected QT interval.
again more likely to be seen in case subjects, with borderline significance (6.0% vs. 3.6%; p ¼ 0.052).
All subjects taking beta-2 agonists were prescribed the medication in the inhaled form; no subject was taking oral beta-2 agonists. Case subjects were also less likely to be on angiotensin receptor blockers (9.2% vs. 13.1%; p ¼ 0.03) and statins (48.5% vs.
67.3%; p < 0.0001); however the proportion taking angiotensin-converting enzyme inhibitors was similar.
COPD AND USE OF SBAs: EFFECTS ON SCD RISK. Table 2 shows the results of the multivariable logistic regres- 
EFFECT OF COPD ON SCD RISK EVALUATED BY
PROPENSITY SCORE-MATCHED ANALYSIS. Analysis was performed as described with a propensity scorematched dataset (330 case and control subjects each).
COPD remained significantly associated with SCD in the propensity score-matched dataset (OR: 3.9; 95% CI: 2.2 to 6.7; p < 0.0001). When the propensity match criteria were made stronger (3-digit matching, with propensity score tenths and hundredths required to be identical), the COPD-SCD association remained similar (OR: 3.2; 95% CI: 1.6 to 6.3).
DISCUSSION
In this population-based study, COPD was found to be significantly associated with SCD after adjustment for LVEF and other cardiovascular risk factors. COPD and SBA were also each independently associated with SCD, which suggests that the COPD-SCD risk was unrelated to SBA use. Furthermore, the presence of both COPD and SBA use had a higher OR for SCD than COPD alone. Although no interaction was seen between COPD and use of SBAs or betablocking drugs, a significant interaction was observed between beta-blockers and SBAs, with beta-blockers appearing to reduce SBA-related SCD risk, likely by blunting the sympathetic activity caused by SBAs. This premise is supported by the fact that compared with patients taking both SBA and beta-blockers, patients taking SBAs only had a significantly higher resting heart rate but had no differences in the frequency of other risk factors.
There was a borderline-significant association seen between long-acting beta-agonists and SCD; however, only a small proportion of cases overall were taking long-acting beta-2 agonists. Because COPD often coexists with other comorbidities, we performed a sensitivity analysis after propensity score matching based on COPD status. The COPD-SCD association was maintained in the results of the propensity-matched dataset. Furthermore, severely ill patients on home oxygen therapy were excluded in our study. Taken together, these results indicate that COPD was associated with SCD risk independent of clinical/ECG risk markers and medications, which also suggests that COPD may exert deleterious effects on the heart via other mechanisms. among patients with acute MI showed that COPD was associated with higher risk of sudden death but not MI or stroke (17) . OSA has been reported to be a risk factor for SCD, and it has been suggested that the presence of both OSA and COPD may result in even higher cardiovascular risk (18, 19) . In the present study, we did not find evidence of a significant interaction between OSA and COPD; this needs further focused evaluation in larger analyses.
It could be argued that COPD may merely be a coexisting condition or a "marker" for the type of person likely to have cardiac disease as well; however, growing evidence suggests that there may be a true link. The exact mechanism underlying the COPD-SCD relationship remains speculative; however, several possibilities can be advanced. Abnormalities of cardiac repolarization including increased QTc and QT dispersion have been identified in COPD patients and shown to be related to SCD (20, 21) , although in the present study, the COPD-SCD association was independent of QTc. A direct relation between hypoxemia and ventricular irritability has been suggested (22) but is likely to be operative only in a small subset of severe cases. However, the increased work of breathing in COPD and resultant increased oxygen demand (23) are additional stressors for a person with heart disease and therefore potential contributors to risk. Another area of increasing focus has been the inflammation that accompanies COPD (24) . Considering the proximity of the lungs to the heart, inflammatory mediators generated in the lung can potentially have adverse consequences for the heart.
A milieu of chronic inflammation could aid progression of atherosclerosis and increase arterial stiffness (25) . COPD has been linked to greater coronary artery calcium scores (26) . Cytokines can recruit leukocytes, contributing to inflammatory plaque rupture (27) .
Inflammatory mediators can also predispose to hypercoagulability and coronary thrombosis (28) .
Autonomic instability that leads to proarrhythmia may play a role as well. Reduced heart rate
Narayanan et al. The COPD-SCD risk association is especially important in the context of primary prevention ICDs, since COPD may contribute to a greater comorbidity burden, and ICD implantation may be less likely in such candidates (35) . However, it has been demonstrated that ICDs reduce mortality in patients with COPD (36) , and the frequency of appropriate ICD shocks is actually higher than in non-COPD subjects (37) . The findings of the current study suggest that the COPD-SCD association would also need to be considered in this decision-making process. formed, owing to the observational nature of the study, we cannot exclude an influence of unmeasured confounders with certainty. In community-based studies of this nature, it is challenging to obtain all aspects of data uniformly for all subjects. Thus, precise data on measures that reflect overall status, such as hospitalizations, were not available. We chose those subjects with LVEF information available for this analysis, and this could result in some bias;
however, it is important to account for ejection fraction, which is the main marker presently used in risk stratification. Finally, our results would need to be confirmed in prospective studies and in other populations before they can be broadly applied.
CONCLUSIONS
In this population-based study, COPD was signifi- 
